HSE considering number of weight loss drug applications

The HSE is currently evaluating several applications for weight-loss drugs, specifically known as GLP-1 medications. These applications are currently under consideration within the HSE's drug reimbursement process. The HSE Drugs Group met recently to assess the drug Mounjaro, but no decision has yet been made by the HSE Senior Leadership Team regarding its availability to public patients.

Mounjaro, produced by Eli Lilly, recently offered a new pricing structure that would result in an annual cost to the State of approximately €2-€3 billion, if it were to be made available on the public system. The HSE indicated that negotiations with manufacturers can be lengthy, and multiple meetings of the Drugs Group may occur before a recommendation can be made to the HSE Senior Management team.

Mounjaro is just one of several weight-loss drugs available privately for type 2 diabetes and chronic weight management. An assessment on another weight-loss drug, Wegovy, is also expected to be completed soon. The HSE emphasized that the State's approach to these drugs raises significant health policy issues, which will require discussions in the coming months with the Department of Health and other stakeholders, particularly in regards to the potential impact on the health budget.

Currently, the HSE does provide a treatment for weight loss called Saxenda to eligible patients who meet specific weight and health criteria.